The authors and the journal apologise for errors that appeared in [Figure 2](#fig1){ref-type="fig"} of this article published in the January issue, Vol **166**, pp 87--97. The errors relate to the number of asterisks given to represent the *P*-values for odd ratios (OR) of the comparisons with 0 to \<6 months interval. In [Figure 2a](#fig1){ref-type="fig"}, the correct data should read as

6 to \<12 months vs 0 to \<6 months: OR 0.66 (95% CI: 0.45 to 0.98)\*

12 to \<18 months vs 0 to \<6 months: OR 0.63 (95% CI: 0.41 to 0.96)\*

and in [Figure 2b](#fig1){ref-type="fig"}, the correct data should read as:

12 to \<18 months vs 0 to \<6 months: OR 0.38 (95% CI: 0.18 to 0.82)\*

and not as published. The correct figure and legend is given below.

![Risk of fracture (adjusted odds with 95% confidence intervals (CIs)) by fracture type: (a) all fractures pooled, (b) clinical vertebral, (c) non-vertebral, and (d) main non-vertebral, in each 6-month interval for the prior bisphosphonate user group. Note: Odds ratios (OR) and 95% confidence intervals (CI) for the comparison with the first 6 months of treatment are given where significant. \**P*\<0.05; \*\**P*\<0.01; \*\*\**P*\<0.001 vs. 0 to \<6 months interval. Main non-vertebral fractures includes forearm/wrist, hip, humerus, leg and sternum/ribs.](EJE110740ef01){#fig1}
